Uncategorized
Omeros reports $18.3 million net loss in third quarter
Omeros reported a net loss of $18.3 million, or $0.54 per share, in the third quarter, compared with a net loss of $13.9 million, or $0.46 per share, in the third quarter of 2013, according to a press release.Operating expenses were $17.3 million, compared with $13.6 million for the same quarter in 2013. This was attributed to preparation for the 2015 U.S. launch of Omidria (phenylephrine 1% and ketorolac 0.3% injection), for use during cataract surgery or IOL replacement, and the advancement of phase 2 clinical programs.